睿昂基因(688217) - 2022 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2022 was ¥99,695,696.51, representing a year-on-year increase of 36.69%[5] - The net profit attributable to shareholders was ¥15,338,890.31, showing a decrease of 13.86% compared to the same period last year[5] - The net profit after deducting non-recurring gains and losses was ¥13,218,302.90, which increased by 17.95% year-on-year[5] - The company experienced a 30.36% increase in operating revenue from the beginning of the year to the reporting period, driven by the growth in COVID-19 testing services[11] - Total operating revenue for the first three quarters of 2022 reached ¥272,407,214.95, an increase of 30.4% compared to ¥208,957,521.99 in the same period of 2021[21] - Net profit for the third quarter of 2022 was ¥43,779,410.06, representing a 11.5% increase from ¥39,164,962.22 in Q3 2021[23] - The net profit attributable to shareholders of the parent company for Q3 2022 was ¥36,621,689.27, down 14.5% from ¥42,736,350.75 in the same quarter of 2021[23] - Basic earnings per share for Q3 2022 were ¥0.66, compared to ¥0.89 in Q3 2021, reflecting a decrease of 25.8%[24] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,017,881,464.38, reflecting a growth of 7.42% compared to the end of the previous year[6] - The total equity attributable to shareholders was ¥932,498,285.81, an increase of 4.91% from the previous year[6] - Total liabilities as of the end of Q3 2022 amounted to ¥69,441,861.25, an increase from ¥50,866,322.16 at the end of Q3 2021[22] - Total liabilities were CNY 57,390,901.74, compared to CNY 33,437,255.25, reflecting an increase of about 71.5%[18] - The company reported a significant increase in accounts payable, which rose to CNY 26,171,231.08 from CNY 11,181,155.21, indicating an increase of approximately 134.8%[18] Cash Flow - The cash flow from operating activities showed a significant decline of 96.07%, totaling ¥1,785,062.59, primarily due to increased costs related to new product market expansion[11] - Cash inflow from operating activities for the first three quarters of 2022 was ¥227,841,010.25, a decrease from ¥244,486,040.42 in the same period of 2021[24] - The net cash flow from operating activities was $1,785,062.59, a significant decrease of 96.1% compared to $45,474,389.59 in the previous year[25] - The total cash and cash equivalents at the end of the period reached $193,323,002.50, an increase from $144,768,891.62, representing a growth of 33.5% year-over-year[26] - The cash outflow from financing activities was $28,829,611.05, compared to $592.28 in the previous year, indicating a substantial increase in financing activities[25] Research and Development - Research and development expenses amounted to ¥18,003,184.24, a decrease of 14.91% from the previous year[6] - Research and development expenses for Q3 2022 were ¥48,473,757.51, down 10.1% from ¥53,941,908.56 in Q3 2021[22] Other Financial Metrics - The basic earnings per share were ¥0.28, down 12.50% from the previous year[6] - The weighted average return on equity was 1.66%, a decrease of 0.37 percentage points compared to the previous year[6] - The company reported a financial expense of -¥6,710,023.16 in Q3 2022, compared to -¥1,190,545.40 in the same quarter of the previous year[22] - The cash received from investment recoveries was $339,325,300.00, a significant increase from $61,050,000.00, representing a growth of 454.3%[25] - The impact of exchange rate changes on cash and cash equivalents was $5,674,689.33, compared to -$941,964.59 in the previous year, indicating a positive shift in currency effects[25]